Early-stage NSCLC Landscape: How the next decade looks like?

The landscape of advanced/metastatic NSCLC has changed dramatically with the approval of immunotherapies and targeted agents in recent years. After metastatic disease, early-stage NSCLC has become a new testing ground for these therapies. Most key players are in the race to position their drugs in this hitherto unexplored territory where surgery, radiotherapy (RT), or chemoradiation (ChemoRT) has remained the mainstay of treatment.

Let’s together explore how early-stage NSCLC is shaping up with the entrenchment of new therapies and what new questions have emerged with this paradigm shift. FutureBridge’s Oncology Analysts in this webinar will cover the:

• Current treatment available for early-stage NSCLC, and therapies likely to emerge in the next 5-7 years
• Recent approvals for IO’s, and targeted therapies in early-stage NSCLC. How they have impacted survival?
• Endpoints appropriate for approvals in early-stage NSCLC
• How therapies could be combined or sequenced to derive maximum benefit?
• Who should be the candidates for neoadjuvant vs. adjuvant treatments in the same settings?
• What is the impact on patient flow and choice of subsequent therapy?
• What are the residual unmet needs?